Only 9% of FDA-registered AI-based healthcare tools include a post-deployment surveillance plan, leaving most medical AI systems without continuous oversight, according to arxiv. This absence creates blind spots for malfunctions, biases, and adverse patient outcomes, clearly prioritizing rapid market entry over patient safety. Regulatory guidelines emphasize continuous AI monitoring, but the vast majority of deployed systems lack adequate surveillance plans, creating a critical tension between policy and practice. Companies using AI save costs, often by lowering safety standards, as noted by adalovelaceinstitute. Without immediate and stringent enforcement of monitoring, AI's societal benefits risk being overshadowed by unmanaged ethical failures and safety compromises.
The Unseen Risks of Unmonitored AI
Governments integrate AI into surveillance systems like cameras and mobile phones, often with tech corporations, as detailed by pmc.ncbi.nlm.nih.gov. The pervasive integration of AI into surveillance systems raises complex ethical accountability challenges for AI post-deployment monitoring. San Francisco's initial ban on police facial recognition in 2019 was later reversed by a public vote to expand surveillance, reported by Nature. Societal ambivalence, as seen in San Francisco's reversal of its facial recognition ban, prioritizes perceived security over privacy, even as the underlying AI systems remain poorly monitored. Such widespread, unmonitored integration normalizes a dangerous trade-off, where convenience and security eclipse fundamental privacy and ethical safeguards. Moreover, artifactual performance decays in AI models can lead to harmful clinical outcomes if misinterpreted, according to pmc.ncbi.nlm.nih.gov. The combination of public ambivalence and technical monitoring challenges in critical infrastructure creates fertile ground for unmanaged risks.
Why Monitoring Falls Short: The Business Reality
Small and medium-sized enterprises (SMEs) face significant AI adoption challenges: lack of explainability, vulnerability to errors, ethical risks, high implementation costs, and a shortage of AI-skilled professionals, highlighted by Nature. The lack of explainability, vulnerability to errors, ethical risks, high implementation costs, and a shortage of AI-skilled professionals directly impede thorough post-deployment monitoring. Security risks like cyberattacks and data breaches further complicate SME AI use, as explained by a report on leveraging trust and ethics for secure and responsible use of AI and LLMs in SMEs. Despite the EU AI Act's emphasis on post-market monitoring, discussed in AuntMinnieEurope, only 9% of FDA-registered AI healthcare tools include surveillance plans. The stark discrepancy between regulatory intent and the low rate of surveillance plan adoption reveals that regulatory intent severely lags practical application, leaving critical sectors exposed to unmonitored risks. The economic drive for AI adoption, often prioritizing cost savings, creates a dangerous incentive to bypass essential post-deployment monitoring and accountability.
The Dehumanizing Lens of AI Development
Research papers analyzing humans often refer to them as 'objects,' obscuring real-world application, according to Nature. The linguistic choice of referring to humans as 'objects' reflects a deeper philosophical issue in AI development: depersonalizing algorithm subjects reduces the urgency for ethical oversight. When human data points become 'objects,' the impetus to monitor AI's real-world impact on individuals diminishes. The academic framing that depersonalizes algorithm subjects reinforces a detachment that undermines the ethical imperative for rigorous post-deployment monitoring. The detachment from human-centric monitoring creates a public blind spot, obscuring the true cost of AI convenience. If foundational research treats humans impersonally, deployed systems will likely not prioritize human-centric monitoring. The perspective that foundational research treats humans impersonally normalizes ethical compromises and safety risks, making the 'human element' an afterthought. The unchecked proliferation of AI without adequate oversight thus becomes a systemic issue, rooted in how researchers conceptualize their subjects.
Charting a Path Towards Accountable AI
Discussions at ECR 2026 in Vienna, reported by AuntMinnieEurope, highlighted the EU AI Act, post-market monitoring, and human factors. Discussions at ECR 2026 in Vienna, which highlighted the EU AI Act, post-market monitoring, and human factors, signal a growing global recognition for structured regulatory frameworks to address AI oversight gaps. The EU AI Act's focus on post-market surveillance offers a template for continuous ethical and performance assessments. However, the disparity between regulatory intent and actual implementation—evidenced by only 9% of FDA-registered AI healthcare tools having surveillance plans, per arxiv—demands more stringent enforcement. Companies are effectively gambling with patient safety, prioritizing market entry over rigorous oversight. If the European Commission finalizes specific implementation guidelines for the EU AI Act by Q3 2026, dictating continuous post-market monitoring for companies like Siemens Healthineers, it appears the industry will face a critical juncture, potentially shifting from rapid deployment to enforced accountability.
